Showing results (2111-2120 of 2,175) with videos related to
Sort By:
Pageof 218
International Journal of Cancer|August 4, 2020
A gene expression-based single sample predictor of lung adenocarcinoma molecular subtype and prognosisHelena Liljedahl, Anna Karlsson, Gudrun N Oskarsdottir, et al.Lancet (London, England)|November 26, 2008
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialEdward S Kim, Vera Hirsh, Tony Mok, et al.Cell Host & Microbe|June 10, 2016
Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer ProtectionCarole J Henry Dunand, Paul E Leon, Min Huang, et al.Journal of the National Cancer Institute|April 19, 2013
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysisChee Khoon Lee, Chris Brown, Richard J Gralla, et al.ESMO Open|December 7, 2017
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancerFiona Blackhall, D Ross Camidge, Alice T Shaw, et al.European Journal of Cancer (Oxford, England : 1990)|December 24, 2013
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29S A Laurie, B J Solomon, L Seymour, et al.Transfusion Medicine Reviews|December 15, 2015
Rationale and Design of the Informing Fresh versus Old Red Cell Management (INFORM) Trial: An International Pragmatic Randomized TrialJohn W Eikelboom, Richard J Cook, Rebecca Barty, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 8, 2016
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trialsJ C-H Yang, L V Sequist, C Zhou, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 20, 2019
A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLCPere Gascón, Rajnish Nagarkar, Martin Šmakal, et al.Physical Review Letters|April 19, 2024
Improved Tensor Current Limit from ^{8}B β Decay Including New Recoil-Order CalculationsB Longfellow, A T Gallant, G H Sargsyan, et al.Pageof 218